Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin
Launched by EISAI CO., LTD. · Apr 17, 2015
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Patients taking long-term low-dose aspirin for prevention of thrombus/embolism at the start of administration of rabeprazole (including patients who start low-dose aspirin on the same day as the start of administration of rabeprazole).
- • 2. Patients with a history of gastric/duodenal ulcers.
- • 3. Patients requiring long-term use of rabeprazole for prevention of recurrence of gastric/duodenal ulcers induced by low-dose aspirin.
- Exclusion criteria:
- • 1. Patients with gastric/duodenal ulcers at the start of administration of rabeprazole.
- • 2. Patients with active upper gastrointestinal bleeding at the start of administration of rabeprazole.
- • 3. Patients with contraindication for rabeprazole.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a global pharmaceutical company headquartered in Japan, dedicated to the research, development, and commercialization of innovative therapeutics that address unmet medical needs. With a strong focus on neurology and oncology, Eisai leverages its extensive expertise in drug discovery and development to advance treatments that improve patient outcomes. Committed to the principles of transparency and collaboration, Eisai actively engages in clinical trials to evaluate the safety and efficacy of its products, ensuring that its research aligns with the highest ethical standards. Through its patient-centric approach, Eisai strives to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Osaka, , Japan
Nagoya, , Japan
Patients applied
Trial Officials
Katsuya Sugizaki
Study Director
Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials